By Kat Greene ( April 24, 2017, 9:00 PM EDT) -- Fresenius Kabi inked a proposed $4.3 billion deal to pick up Akorn, a maker and marketer of prescription and over-the-counter drugs that complement Fresenius' injections-focused products, in an arrangement advised by Allen & Overy LLP, Cravath Swaine & Moore LLP and Polsinelli PC, the companies said Monday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.